Urinary concentrations and brief description of 12 cannabinoids and cannabinoid-metabolites (ng/mL) among 103 eligible participants in Healthy Start
| Cannabinoid . | Abbreviation . | Brief description . | n (% detected) . | Mean ± SD . | Min . | Max . |
|---|---|---|---|---|---|---|
| Δ9-tetrahydrocannabinol | THC | -Most abundant cannabinoid -Partial agonist of CB1 and CB2 receptors in brain, pancreas, and adipose tissue -Fetal exposure associated with β-cell apoptosis | 5 (5%) | 0.4 ± 0.2 | 0.3 | 0.9 |
| 11-hydroxy-Δ9-tetrahydrocannabinol | 11OH-THC | -Primary metabolite of THC | 1 (1%) | 0.8 | - | - |
| 11-nor-delta 9-carboxy-tetrahydrocannabinol | THC-COOH | -Secondary metabolite of THC | 9 (9%) | 5.2 ± 6.2 | 0.3 | 17.6 |
| Δ9-tetrahydrocannabinol-9-carboxylic acid glucuronide | THC-C-gluc | -Glucuronidated THC-COOH | 12 (12%) | 214.7 ± 316.2 | 0 | 779.8 |
| Δ9-tetrahydrocannabinol glucuronide | THC-gluc | -Glucuronidated THC | 8 (8%) | 3.8 ± 4.0 | 0.4 | 12.0 |
| Cannabidiol | CBD | -Second most abundant cannabinoid -Modulates effects of THC -Low affinity for CB1 and CB2 receptors | 5 (5%) | 0.6 ± 0.1 | 0.4 | 0.7 |
| Cannabidiol glucuronide | CBD-gluc | -Glucuronidated CBD | 1 (1%) | 1.0 | - | - |
| Cannabichromene | CBC | -Agonist of TRPA1 receptors -Anti-inflammatory effects | 1 (1%) | 0.7 | - | - |
| Cannabinol | CBN | -Mildly psychotropic cannabinoid | 0 | - | - | - |
| Cannabigerol | CBG | -Antagonist of CB1 receptors | 2 (2%) | 0.3 ± 0.2 | 0.2 | 0.5 |
| Δ9-tetrahydrocannabivarin | THCV | -Partial agonist of CB2 receptors -Antagonizes CB agonists (eg, THC) | 1 (1%) | 0.7 | - | - |
| Cannabidivarin | CBDV | -Homolog of CBD | 0 | - | - | - |
| Cannabinoid . | Abbreviation . | Brief description . | n (% detected) . | Mean ± SD . | Min . | Max . |
|---|---|---|---|---|---|---|
| Δ9-tetrahydrocannabinol | THC | -Most abundant cannabinoid -Partial agonist of CB1 and CB2 receptors in brain, pancreas, and adipose tissue -Fetal exposure associated with β-cell apoptosis | 5 (5%) | 0.4 ± 0.2 | 0.3 | 0.9 |
| 11-hydroxy-Δ9-tetrahydrocannabinol | 11OH-THC | -Primary metabolite of THC | 1 (1%) | 0.8 | - | - |
| 11-nor-delta 9-carboxy-tetrahydrocannabinol | THC-COOH | -Secondary metabolite of THC | 9 (9%) | 5.2 ± 6.2 | 0.3 | 17.6 |
| Δ9-tetrahydrocannabinol-9-carboxylic acid glucuronide | THC-C-gluc | -Glucuronidated THC-COOH | 12 (12%) | 214.7 ± 316.2 | 0 | 779.8 |
| Δ9-tetrahydrocannabinol glucuronide | THC-gluc | -Glucuronidated THC | 8 (8%) | 3.8 ± 4.0 | 0.4 | 12.0 |
| Cannabidiol | CBD | -Second most abundant cannabinoid -Modulates effects of THC -Low affinity for CB1 and CB2 receptors | 5 (5%) | 0.6 ± 0.1 | 0.4 | 0.7 |
| Cannabidiol glucuronide | CBD-gluc | -Glucuronidated CBD | 1 (1%) | 1.0 | - | - |
| Cannabichromene | CBC | -Agonist of TRPA1 receptors -Anti-inflammatory effects | 1 (1%) | 0.7 | - | - |
| Cannabinol | CBN | -Mildly psychotropic cannabinoid | 0 | - | - | - |
| Cannabigerol | CBG | -Antagonist of CB1 receptors | 2 (2%) | 0.3 ± 0.2 | 0.2 | 0.5 |
| Δ9-tetrahydrocannabivarin | THCV | -Partial agonist of CB2 receptors -Antagonizes CB agonists (eg, THC) | 1 (1%) | 0.7 | - | - |
| Cannabidivarin | CBDV | -Homolog of CBD | 0 | - | - | - |
Abbreviations: CB1, cannabinoid type 1; CB2, cannabinoid type 2.
Urinary concentrations and brief description of 12 cannabinoids and cannabinoid-metabolites (ng/mL) among 103 eligible participants in Healthy Start
| Cannabinoid . | Abbreviation . | Brief description . | n (% detected) . | Mean ± SD . | Min . | Max . |
|---|---|---|---|---|---|---|
| Δ9-tetrahydrocannabinol | THC | -Most abundant cannabinoid -Partial agonist of CB1 and CB2 receptors in brain, pancreas, and adipose tissue -Fetal exposure associated with β-cell apoptosis | 5 (5%) | 0.4 ± 0.2 | 0.3 | 0.9 |
| 11-hydroxy-Δ9-tetrahydrocannabinol | 11OH-THC | -Primary metabolite of THC | 1 (1%) | 0.8 | - | - |
| 11-nor-delta 9-carboxy-tetrahydrocannabinol | THC-COOH | -Secondary metabolite of THC | 9 (9%) | 5.2 ± 6.2 | 0.3 | 17.6 |
| Δ9-tetrahydrocannabinol-9-carboxylic acid glucuronide | THC-C-gluc | -Glucuronidated THC-COOH | 12 (12%) | 214.7 ± 316.2 | 0 | 779.8 |
| Δ9-tetrahydrocannabinol glucuronide | THC-gluc | -Glucuronidated THC | 8 (8%) | 3.8 ± 4.0 | 0.4 | 12.0 |
| Cannabidiol | CBD | -Second most abundant cannabinoid -Modulates effects of THC -Low affinity for CB1 and CB2 receptors | 5 (5%) | 0.6 ± 0.1 | 0.4 | 0.7 |
| Cannabidiol glucuronide | CBD-gluc | -Glucuronidated CBD | 1 (1%) | 1.0 | - | - |
| Cannabichromene | CBC | -Agonist of TRPA1 receptors -Anti-inflammatory effects | 1 (1%) | 0.7 | - | - |
| Cannabinol | CBN | -Mildly psychotropic cannabinoid | 0 | - | - | - |
| Cannabigerol | CBG | -Antagonist of CB1 receptors | 2 (2%) | 0.3 ± 0.2 | 0.2 | 0.5 |
| Δ9-tetrahydrocannabivarin | THCV | -Partial agonist of CB2 receptors -Antagonizes CB agonists (eg, THC) | 1 (1%) | 0.7 | - | - |
| Cannabidivarin | CBDV | -Homolog of CBD | 0 | - | - | - |
| Cannabinoid . | Abbreviation . | Brief description . | n (% detected) . | Mean ± SD . | Min . | Max . |
|---|---|---|---|---|---|---|
| Δ9-tetrahydrocannabinol | THC | -Most abundant cannabinoid -Partial agonist of CB1 and CB2 receptors in brain, pancreas, and adipose tissue -Fetal exposure associated with β-cell apoptosis | 5 (5%) | 0.4 ± 0.2 | 0.3 | 0.9 |
| 11-hydroxy-Δ9-tetrahydrocannabinol | 11OH-THC | -Primary metabolite of THC | 1 (1%) | 0.8 | - | - |
| 11-nor-delta 9-carboxy-tetrahydrocannabinol | THC-COOH | -Secondary metabolite of THC | 9 (9%) | 5.2 ± 6.2 | 0.3 | 17.6 |
| Δ9-tetrahydrocannabinol-9-carboxylic acid glucuronide | THC-C-gluc | -Glucuronidated THC-COOH | 12 (12%) | 214.7 ± 316.2 | 0 | 779.8 |
| Δ9-tetrahydrocannabinol glucuronide | THC-gluc | -Glucuronidated THC | 8 (8%) | 3.8 ± 4.0 | 0.4 | 12.0 |
| Cannabidiol | CBD | -Second most abundant cannabinoid -Modulates effects of THC -Low affinity for CB1 and CB2 receptors | 5 (5%) | 0.6 ± 0.1 | 0.4 | 0.7 |
| Cannabidiol glucuronide | CBD-gluc | -Glucuronidated CBD | 1 (1%) | 1.0 | - | - |
| Cannabichromene | CBC | -Agonist of TRPA1 receptors -Anti-inflammatory effects | 1 (1%) | 0.7 | - | - |
| Cannabinol | CBN | -Mildly psychotropic cannabinoid | 0 | - | - | - |
| Cannabigerol | CBG | -Antagonist of CB1 receptors | 2 (2%) | 0.3 ± 0.2 | 0.2 | 0.5 |
| Δ9-tetrahydrocannabivarin | THCV | -Partial agonist of CB2 receptors -Antagonizes CB agonists (eg, THC) | 1 (1%) | 0.7 | - | - |
| Cannabidivarin | CBDV | -Homolog of CBD | 0 | - | - | - |
Abbreviations: CB1, cannabinoid type 1; CB2, cannabinoid type 2.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
